Cover Image
市場調查報告書

囊狀纖維化症:開發中產品分析

Cystic Fibrosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232829
出版日期 內容資訊 英文 389 Pages
訂單完成後即時交付
價格
Back to Top
囊狀纖維化症:開發中產品分析 Cystic Fibrosis - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 389 Pages
簡介

囊狀纖維化症,是對生成粘液及出汗、消化液的細胞起作用的遺傳性疾病。症狀為喘鳴、呼吸急促、反復的肺感染疾病、鼻腔的發炎,重度的便秘等。罹患囊狀纖維化症深度有關於遺傳的要素、人種(多為北歐圈的白人)。治療利用抗菌藥、濃性粘液的分解藥、支氣管擴張藥、口服的胰酵素劑等。

本報告提供囊狀纖維化症治療藥的開發情形的相關調查,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等。

簡介

  • 調查範圍

囊狀纖維化症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

囊狀纖維化症:企業正在開發的治療藥

囊狀纖維化症:大學/機關研究中的治療藥

囊狀纖維化症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

囊狀纖維化症:企業開發中的產品

囊狀纖維化症:大學/機關研究中的產品

囊狀纖維化症的治療藥開發作的企業

  • Actelion Ltd
  • Akari Therapeutics, Plc
  • Alaxia SAS
  • AlgiPharma AS
  • AmpliPhi Biosciences Corporation
  • Arcturus Therapeutics, Inc
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Calista Therapeutics, Inc.
  • Carolus Therapeutics, Inc.
  • Celtaxsys, Inc.
  • Chiesi Farmaceutici SpA
  • Cilian AG
  • Concert Pharmaceuticals, Inc.
  • Corbus pharmaceuticals, Inc.
  • CSA Biotechnologies LLC
  • Cyclacel Pharmaceuticals, Inc.
  • DiscoveryBiomed, Inc.
  • Editas Medicine, Inc.
  • Errant Gene Therapeutics, LLC
  • Galapagos NV
  • GlaxoSmithKline Plc
  • Grifols, S.A.
  • Grupo Praxis Pharmaceutical SA
  • Horizon Pharma Plc
  • Insmed Incorporated
  • Invion Limited
  • JHL Biotech, Inc.
  • Kamada Ltd.
  • La Jolla Pharmaceutical Company
  • Lamellar Biomedical Ltd
  • Laurent Pharmaceuticals Inc.
  • Mast Therapeutics, Inc.
  • Merck & Co., Inc.
  • Microbion Corporation
  • Mucokinetica Ltd.
  • NanoBio Corporation
  • Nivalis Therapeutics, Inc.
  • Nostrum Pharmaceuticals, LLC
  • Novabiotics Limited
  • Novartis AG
  • OSE Pharma SA
  • Parion Sciences, Inc.
  • Pfizer Inc.
  • Pharmaxis Limited
  • PhaseBio Pharmaceuticals, Inc.
  • Polyphor Ltd.
  • Progenra, Inc.
  • ProMetic Life Sciences Inc.
  • ProQR Therapeutics N.V.
  • Protalix BioTherapeutics, Inc.
  • Proteostasis Therapeutics, Inc.
  • PTC Therapeutics, Inc.
  • Pulmatrix, Inc.
  • Raptor Pharmaceutical Corp.
  • ReveraGen BioPharma, Inc.
  • Savara Inc.
  • Serendex Pharmaceuticals A/S
  • Shionogi & Co., Ltd.
  • Shire Plc
  • Synovo GmbH
  • TGV-Laboratories
  • The International Biotechnology Center (IBC) Generium
  • Verona Pharma Plc
  • Vertex Pharmaceuticals Incorporated
  • Xenetic Biosciences (UK) Limited
  • Zambon Company S.p.A.

囊狀纖維化症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (ammonium chloride + citric acid + sodium citrate)
  • (fosfomycin + tobramycin)
  • (ivacaftor + tezacaftor)
  • ABPA1
  • acebilustat
  • Aerucin
  • alpha proteinase inhibitor (human) second generation
  • ALX09
  • amikacin sulphate
  • amlexanox
  • Anti-Pseudomonas IgY
  • Antimicrobial Drug for Cystic Fibrosis
  • AT10
  • ataluren
  • AZD634
  • BI43651
  • Biologics for Cystic Fibrosis Lung Infections
  • Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis
  • Brevenal
  • Calcaftor
  • CFX
  • CSA3
  • CSY073
  • CT009
  • CTP56
  • cysteamine IR
  • dapsone
  • Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis
  • doripenem
  • dornase alfa biosimilar
  • dornase alfa biosimilar
  • Drugs for Cystic Fibrosis
  • FDL69
  • fenretinide
  • Gene Therapy to Activate CFTR for Cystic Fibrosis
  • Gene Therapy to Activate CFTR for Cystic Fibrosis
  • Gene Therapy to Activate CFTR Gene for Cystic Fibrosis
  • GLPG837
  • GLPG837 + GLPG222 + GLPG665
  • GLPG222
  • GLPG451
  • GLPG665
  • GLPG737
  • GLPG851
  • glycerol phenylbutyrate
  • GSK225745
  • itraconazole
  • JBT01
  • kenpaullone
  • levofloxacin
  • levofloxacin
  • LJPC0Sa
  • LJPC0Sb
  • LMS11
  • LUNAR-CF
  • mannitol
  • MBN01
  • MG77
  • miglustat
  • MKA04
  • molgramostim
  • Mul867
  • N1115
  • N1138
  • N1169
  • nadolol
  • NB01
  • nitric oxide
  • nitric oxide
  • Nu
  • NVPQBE70
  • Oligomer G for Cystic Fibrosis
  • ORP00
  • P055
  • PAC-IC
  • Panaecin
  • PB1
  • PB046
  • PB120
  • PBI050
  • POL014
  • PRX10
  • PTI30
  • PTI28
  • PTIC811
  • PTIP71
  • PulmoXen
  • PXS728A
  • QR10
  • QRX
  • Recombinant A1PI
  • Recombinant Acid Ceramidase Replacement for Farber Disease and Cystic Fibrosis
  • Recombinant Enzyme to Target DNA for Cystic Fibrosis
  • Recombinant Protein for Infectious Diseases and Respiratory Disorders
  • riociguat
  • RPL54
  • S226
  • S229
  • S8
  • seliciclib
  • SHP37
  • Small Molecule for Cystic Fibrosis
  • Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis
  • Small Molecule to Activate CFTR for Cystic Fibrosis
  • Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease
  • Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD
  • Small Molecules for Bacterial Infections
  • Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis
  • Small Molecules for Cystic Fibrosis
  • Small Molecules to Activate CFTR for Cystic Fibrosis
  • Small Molecules to Activate CFTR Protein for Cystic Fibrosis
  • Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis
  • Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis
  • Small Molecules to Block SCNN1 for Cystic Fibrosis
  • Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis
  • Small Molecules to Inhibit USP8 for Cystic Fibrosis
  • sodium nitrite
  • solithromycin
  • SP4
  • SP
  • Stem Cell Therapy for Cystic Fibrosis
  • SYGN13
  • SYGN03
  • tritoqualine
  • vamorolone
  • vancomycin hydrochloride
  • VX52
  • VX71
  • VX40
  • ZP46

囊狀纖維化症:最近的開發平台趨勢

囊狀纖維化症:暫停中的計劃

囊狀纖維化症:開發中止的產品

囊狀纖維化症:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8474IDB

Summary

Global Markets Direct's, 'Cystic Fibrosis - Pipeline Review, H2 2016', provides an overview of the Cystic Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis
  • The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Cystic Fibrosis Overview
  • Therapeutics Development
  • Cystic Fibrosis - Therapeutics under Development by Companies
  • Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Cystic Fibrosis - Pipeline Products Glance
  • Cystic Fibrosis - Products under Development by Companies
  • Cystic Fibrosis - Products under Investigation by Universities/Institutes
  • Cystic Fibrosis - Companies Involved in Therapeutics Development
  • Cystic Fibrosis - Therapeutics Assessment
  • Drug Profiles
  • Cystic Fibrosis - Dormant Projects
  • Cystic Fibrosis - Discontinued Products
  • Cystic Fibrosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Cystic Fibrosis, H2 2016
  • Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Cystic Fibrosis - Pipeline by Actelion Ltd, H2 2016
  • Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2016
  • Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2016
  • Cystic Fibrosis - Pipeline by AmpliPhi Biosciences Corporation, H2 2016
  • Cystic Fibrosis - Pipeline by Arch Biopartners, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Arcturus Therapeutics, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Cystic Fibrosis - Pipeline by AstraZeneca Plc, H2 2016
  • Cystic Fibrosis - Pipeline by Bayer AG, H2 2016
  • Cystic Fibrosis - Pipeline by BioAegis Therapeutics, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Cystic Fibrosis - Pipeline by Calista Therapeutics, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Celtaxsys, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2016
  • Cystic Fibrosis - Pipeline by Cilian AG, H2 2016
  • Cystic Fibrosis - Pipeline by Concert Pharmaceuticals, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by CRISPR Therapeutics, H2 2016
  • Cystic Fibrosis - Pipeline by CSA Biotechnologies LLC , H2 2016
  • Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by DiscoveryBiomed, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Editas Medicine, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Eloxx Pharmaceuticals, Ltd., H2 2016
  • Cystic Fibrosis - Pipeline by Errant Gene Therapeutics, LLC, H2 2016
  • Cystic Fibrosis - Pipeline by Eumedica SA, H2 2016
  • Cystic Fibrosis - Pipeline by Galapagos NV, H2 2016
  • Cystic Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2016
  • Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H2 2016
  • Cystic Fibrosis - Pipeline by ID Pharma Co., Ltd., H2 2016
  • Cystic Fibrosis - Pipeline by Immun System I.M.S. AB, H2 2016
  • Cystic Fibrosis - Pipeline by Insmed Incorporated, H2 2016
  • Cystic Fibrosis - Pipeline by Invion Limited, H2 2016
  • Cystic Fibrosis - Pipeline by JHL Biotech, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Kamada Ltd., H2 2016
  • Cystic Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Cystic Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H2 2016
  • Cystic Fibrosis - Pipeline by Lakewood-Amedex Inc, H2 2016
  • Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H2 2016
  • Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Mast Therapeutics, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Merck & Co., Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Microbion Corporation, H2 2016
  • Cystic Fibrosis - Pipeline by Mucokinetica Ltd., H2 2016
  • Cystic Fibrosis - Pipeline by Nivalis Therapeutics, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Novabiotics Limited, H2 2016
  • Cystic Fibrosis - Pipeline by Novartis AG, H2 2016
  • Cystic Fibrosis - Pipeline by OSE Immunotherapeutics, H2 2016
  • Cystic Fibrosis - Pipeline by Paranta Biosciences Limited, H2 2016
  • Cystic Fibrosis - Pipeline by Parion Sciences, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Pfizer Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
  • Cystic Fibrosis - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Polyphor Ltd., H2 2016
  • Cystic Fibrosis - Pipeline by Progenra, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Cystic Fibrosis - Pipeline by ProQR Therapeutics N.V., H2 2016
  • Cystic Fibrosis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Proteostasis Therapeutics, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by PTC Therapeutics, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Pulmatrix, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H2 2016
  • Cystic Fibrosis - Pipeline by ReveraGen BioPharma, Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Savara Inc., H2 2016
  • Cystic Fibrosis - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Cystic Fibrosis - Pipeline by Shire Plc, H2 2016
  • Cystic Fibrosis - Pipeline by Synovo GmbH, H2 2016
  • Cystic Fibrosis - Pipeline by TGV-Laboratories, H2 2016
  • Cystic Fibrosis - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
  • Cystic Fibrosis - Pipeline by Verona Pharma Plc, H2 2016
  • Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
  • Cystic Fibrosis - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016
  • Cystic Fibrosis - Pipeline by Zambon Company S.p.A., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cystic Fibrosis - Dormant Projects, H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..1), H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..2), H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..3), H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..4), H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..5), H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..6), H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..7), H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..8), H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..9), H2 2016
  • Cystic Fibrosis - Dormant Projects (Contd..10), H2 2016
  • Cystic Fibrosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cystic Fibrosis, H2 2016
  • Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top